Loading...
Market
Will Pfizer announce a new treatment for sickle cell disease by September 25, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Pfizer's official press releases and announcements
Story
Pfizer ($PFE) Withdraws Sickle Cell Drug Oxbryta from Global Markets
Sep 25, 2024, 09:07 PM
Pfizer Inc. ($PFE) announced on Wednesday that it is voluntarily withdrawing all lots of its sickle cell disease treatment Oxbryta (voxelotor) from worldwide markets. The decision comes after data indicated an imbalance in vaso-occlusive crises and fatal events associated with the drug. This withdrawal marks a significant setback for Pfizer, following its $5.4 billion acquisition of Global Blood Therapeutics, the original developer of Oxbryta. The company stated that the overall benefit of Oxbryta no longer outweighs the risks involved.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other major markets • 25%
Not approved in any major market • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
